Closed Loop Ventilation - Exam Ready Answer (Anaesthesia)

Definition and Conceptual Framework

1. Sensor - measures the physiological signal (e.g. SpO2, EtCO2, tidal volume, airway pressure, respiratory mechanics)
2. Controller - an algorithm (rule-based, adaptive, or AI-driven) that processes the signal and computes the required output change
3. Actuator - the ventilator output (inspiratory pressure, rate, FiO2, PEEP, I:E ratio)

Classification of Targeting Schemes (Chatburn's Taxonomy)

Clinically Available Closed Loop Modes

1. Dual-Control Modes (most widely available)

• Sets an inspiratory pressure target, adjusts it breath-by-breath to achieve a clinician-set volume target
• Loop operates on a breath-to-breath timescale
• Benefit: pressure-controlled flow waveform (patient comfort) with volume guarantee
• Limitation: can increase pressure in stiff lungs, risking barotrauma if volume target is set too high; known to create "reverse triggering" and patient-ventilator dyssynchrony

2. Adaptive Support Ventilation (ASV - Hamilton Medical)

• Clinician sets % Minute Ventilation (typically 100%) and body weight
• Ventilator calculates optimal VT and RR to achieve that MV with minimum work (based on Otis' equation - minimises respiratory work by choosing the most efficient VT/RR combination)
• Automatically adjusts between controlled and supported modes as patient effort changes
• Adjusts PEEP and FiO2 with INTELLiVENT add-on (see below)

3. INTELLiVENT-ASV (Hamilton Medical)

• Most sophisticated commercially available system
• Adds closed-loop FiO2 and PEEP control targeting SpO2 and EtCO2 within set ranges
• Covers virtually all ventilator settings in one algorithm
• Has received the most clinical trial attention (see ACTIVE trial below)

4. SmartCare/PS (Dräger)

• Automated weaning system operating in PSV mode
• Adjusts pressure support to keep patient within a "comfort zone" of RR, VT, and EtCO2
• When criteria are met, automatically conducts SBT and recommends extubation
• Evidence: reduces weaning time in post-operative patients

5. Volume Support Ventilation (VSV)

• Patient-triggered, pressure-limited, volume-targeted
• Reduces support as patient effort increases - conceptually "auto-weans"
• Limitations: may not wean appropriately if volume target is set too high; can cause excessive work if set too low; PEEP may develop in obstruction

6. Proportional Assist Ventilation + (PAV+) and NAVA

• Servo-targeting modes - track patient demand in real time
• PAV+ uses respiratory mechanics to deliver a proportion of the patient's own effort
• NAVA uses diaphragm EMG signal (Edi) as the direct driver of support
• These are "assistance amplifiers" rather than target-driven controllers

Intraoperative Closed Loop Ventilation

• Automated adjustment of VT (6 ml/kg PBW), RR, and PEEP to maintain EtCO2 and SpO2 targets
• Systems like ASV can be used intraoperatively to maintain lung-protective settings
• A randomised trial in cardiac surgery patients found fully automated ventilation increased time spent within lung-protective thresholds and accelerated return to spontaneous breathing vs. conventional ventilation

• Closed-loop FiO2 controllers target SpO2 within an individualised range
• A meta-analysis demonstrated substantially more time within SpO2 targets and signals of less hypoxemia with closed-loop O2 control (particularly relevant in neonates/ARDS)

• BIS-guided propofol TCI (e.g. McSleepy, iControl-RP): BIS target drives propofol infusion rate
• Haemodynamic-guided fluid and vasopressor delivery: arterial waveform analysis drives IV fluid and vasopressor algorithms (e.g. Acumen Hypotension Prediction Index / closed-loop vasopressor)
• These represent the future of fully integrated "closed-loop anaesthesia"

Key Clinical Evidence (Exam-Level Citations)

Systematic Review - Goossen et al. (2024) - European Journal of Anaesthesiology

• 51 RCTs comparing CLV vs. conventional ventilation in ICU
• CLV: enhanced management of lung-protective variables, minimal adverse events
• Patient outcomes: possible improvements but individual studies underpowered
• Workload: CLV reduced ICU professional workload (fewer manual adjustments)
• Conclusion: CLV at least as effective as ICU professionals for ventilator management; reduces workload; insufficient data to confirm mortality benefit

Cochrane Review - Rose et al. (2025)

• 62 RCTs, 5,052 participants (59 adult, 3 paediatric)
• Evaluated 10 commercially available closed-loop systems
• Moderate-certainty evidence:
  • Mechanical ventilation duration: -24% relative reduction (MD -0.28 log hours, 95% CI -0.36 to -0.20)
  • ICU LOS: -14% relative reduction
  • Hospital LOS: -10% relative reduction
  • Mortality: no difference (RR 0.94, 95% CI 0.82-1.07)
  • Reintubation: reduced (RR 0.73, 95% CI 0.59-0.89)
  • NIV post-extubation: reduced (RR 0.74)
  • Tracheostomy: reduced (RR 0.75)
  • Prolonged ventilation: reduced (RR 0.54)
• This is the most powerful evidence to date - quote it in exams

ACTIVE Trial - Sinnige et al. (JAMA, 2026) - The landmark negative trial

• 7 ICUs, Netherlands and Switzerland; 1,201 patients analysed (1,514 randomised)
• INTELLiVENT-ASV vs. protocolised conventional ventilation
• Primary outcome: ventilator-free days at day 28
  • CLV group: 16.7 days (IQR 0.0-26.1)
  • Conventional: 16.3 days (IQR 0.0-26.5)
  • OR 0.91 (95% CI 0.77-1.06); P = 0.23 - no significant difference
• Secondary: ventilation quality higher with CLV; severe hypercapnia and hypoxemia less frequent in CLV group; fewer rescue therapies (primarily prone positioning) in CLV group (trend, not significant after multiplicity adjustment)
• Mortality: no difference
• Interpretation: In a mixed ICU population where most patients extubated within 3 days, automated CLV did not improve VFDs. Supports equipoise - CLV is safe and improves quality metrics but does not reduce hard outcomes in unselected critically ill patients

Physiology-Guided Personalised Ventilation - Merola et al. (Frontiers in Medicine, 2026)

• Reviews the conceptual shift from protocol-driven to physiology-guided, personalised ventilation
• Highlights closed-loop systems, adaptive control algorithms, and computational modelling as tools to reduce VILI
• Bedside tools (EIT, oesophageal manometry, lung US) + CLV as complementary strategies

Advantages of Closed Loop Ventilation

1. Continuous adaptation - responds to dynamic changes in respiratory mechanics, patient effort, and lung compliance without waiting for clinical review
2. Greater adherence to lung-protective targets - more time within set VT, plateau pressure, driving pressure, SpO2, and EtCO2 limits than clinician-managed ventilation
3. Reduced workload - fewer manual adjustments required from nurses and physicians
4. Earlier recognition of weaning readiness - automated systems can identify return of spontaneous effort and trigger SBT earlier
5. Reduced variability - less inter-clinician and inter-shift variation in ventilatory management
6. Safety data - adverse events rare in published trials; comparable or fewer complications vs. conventional

Limitations and Concerns

1. Hard outcome data is lacking - the ACTIVE trial (JAMA 2026) showed no improvement in VFDs or mortality in unselected ICU patients despite better quality metrics
2. Algorithmic blind spots - CLV algorithms cannot detect patient-ventilator dyssynchrony, auto-PEEP, or position changes; clinical oversight remains essential
3. Population specificity - current systems not validated in ARDS, neurocritical care (where PaCO2 targets are precise and clinician-specified), or patients with complex non-pulmonary physiology
4. Proprietary systems - INTELLiVENT requires Hamilton ventilators; SmartCare requires Dräger; limits portability and cross-institutional comparison
5. Overriding patient physiology - in conditions like severe obstructive physiology (auto-PEEP), the algorithm may make inappropriate adjustments
6. Workload paradox - setup, troubleshooting, and understanding algorithm behaviour may increase cognitive load for unfamiliar users
7. Regulatory and medicolegal - autonomous ventilator decisions raise questions about accountability when adverse events occur
8. Cost - advanced systems carry significant capital and maintenance costs

Future Directions

1. AI-powered controllers - reinforcement learning models trained on large datasets to personalise ventilation in real time beyond the current rule-based/mathematical algorithms; can learn patient-specific physiology rather than applying population-level heuristics
2. Multi-parameter closed loop - integration of EIT (regional ventilation), oesophageal manometry (transpulmonary pressure), and diaphragm US into the feedback loop for true physiology-guided individualisation
3. Fully integrated closed-loop anaesthesia - single overarching system controlling ventilation, depth of anaesthesia (BIS-guided TCI), haemodynamics (fluid/vasopressor), temperature, and glucose simultaneously. The anaesthesiologist becomes an overseer rather than a manual operator
4. Intraoperative driving pressure guidance - a JAMA 2025 trial evaluated driving pressure-guided high PEEP vs. standard low PEEP intraoperatively for postoperative pulmonary complications; integrating this into CLV intraoperative algorithms is actively explored
5. Perioperative continuity - seamless transition of CLV from operating theatre to ICU to ward, maintaining personalised targets across the whole perioperative period
6. Paediatric and neonatal development - current evidence base is predominantly adult; dedicated paediatric CLV algorithms are being developed
7. CLV in ARDS - the ACTIVE trial enrolled a heterogeneous ICU population; a dedicated ARDS CLV trial would address the subgroup most likely to benefit

Summary for Exam (Viva Points)

• CLV replaces the clinician as the "controller" in the negative feedback loop, using sensors to adjust ventilator settings in real time
• Commercially available levels of automation: dual-control (PRVC) → adaptive (ASV) → closed-loop multi-parameter (INTELLiVENT-ASV, SmartCare)
• Best evidence: Cochrane 2025 (62 RCTs) - moderate certainty for 24% reduction in MV duration, 14% shorter ICU LOS, no mortality difference
• Landmark negative trial: ACTIVE/JAMA 2026 - INTELLiVENT-ASV did not increase VFDs vs. protocolised conventional ventilation, though ventilation quality was better
• CLV is safe, improves process metrics, reduces workload - but has not yet demonstrated a mortality benefit
• Future: AI-driven, multi-sensor, fully integrated perioperative closed-loop systems; anaesthesiologist as supervisor not operator
• Key caveat: clinical oversight remains mandatory; algorithms cannot replace judgement in complex or unusual physiology

• Goossen et al. 2024 - Eur J Anaesthesiol (systematic review, 51 RCTs)
• Rose et al. 2025 - Cochrane (62 RCTs, 5,052 patients)
• Sinnige et al. JAMA 2026 - ACTIVE trial (1,201 patients, landmark RCT)
• Merola et al. Front Med 2026 (physiology-guided personalised ventilation review)
• Murray & Nadel's Respiratory Medicine - Automated Weaning Strategies section
• Morgan & Mikhail's Clinical Anaesthesiology 7e - Targeting Schemes